Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXA6B3)

Drug Name
RO-4929097 Drug Info
Synonyms
RO4929097; 847925-91-1; Ro 4929097; UNII-KK8645V7LE; KK8645V7LE; RG-4733; N1-[(7S)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropropyl)propanediamide; n1-((7s)-6,7-dihydro-6-oxo-5h-dibenz(b,d)azepin-7-yl)-2,2-dimethyl-n3-(2,2,3,3,3-pentafluoropropyl)propanediamide; OJPLJFIFUQPSJR-INIZCTEOSA-N; cc-19; MLS006011071; SCHEMBL1376366; GTPL7338; CHEBI:86474; DTXSID20233833; C22H20F5N3O3; MolPort-016-633-243; BCPP000088; EX-A1750; ZINC43208642; ABP000966; s1575; AKOS027250816
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Cross-matching ID
PubChem CID
49867930
ChEBI ID
CHEBI:86474
CAS Number
CAS 847925-91-1
TTD Drug ID
DMXA6B3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Gamma-secretase (GS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nirogacestat DMUP5Z0 Desmoid tumour 2F7C Approved [3]
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [4]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [5]
Semagacestat DML83IW Parkinson disease 8A00.0 Phase 3 [6]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [4]
MK-0752 DMLTAES Alzheimer disease 8A20 Phase 2 [7]
BMS-708163 DM51LTG Alzheimer disease 8A20 Phase 2 [8]
CHF-5074 DMTE071 Alzheimer disease 8A20 Phase 2 [9]
AL102 DMCTWIB Desmoid tumour 2F7C Phase 2 [10]
SPI-014 DM5IPUS Alzheimer disease 8A20 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gamma-secretase (GS) TT9W8GU APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7338).
2 Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
3 Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
4 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
5 Clinical pipeline report, company report or official report of Roche (2009).
6 A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
7 Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
8 Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
9 CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
10 Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.
11 Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756.